Inspection Record

IntelliPharmaCeutics Corp. — Health Canada Inspection Findings

Health CanadaInspected 2022-05-31 10 findingsDeviation, CAPA, and investigationStability and storageOther quality systemEquipment and facilityTraining and personnelComplaint and recall handlingCleaning validation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

The investigation, handling, and/or reporting of test results that were out-of-specification was inadequate.

2Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

3Stability and storage

The temperature and/or humidity control was inadequate.

4Other quality system

The controls were inadequate for creating, modifying, reviewing, storing, and/or retrieving records.

5Equipment and facility

The validation of equipment or the planned maintenance of equipment was inadequate.

6Training and personnel

The ongoing training of personnel was inadequate.

8Other quality system

The implementation of a self-inspection program was inadequate.

9Other quality system

The master production documents were inadequate.

10Cleaning validation

The implementation, effectiveness, and/or validation of the cleaning procedures was inadequate for preventing unsanitary conditions.

About this record

Extracted automatically from the document of the Health Canada inspection on 2022-05-31. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

IntelliPharmaCeutics Corp. company profile — full historyAll Health Canada findings Health Canada documents, 2022 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.